Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Driving Performance Study of TS-142 in Healthy Subjects
NCT04696952Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Standard deviation of lateral position (SDLP) on day 2 and Standard deviation of lateral position (SDLP) on day 9. Started Jan 2021; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04696952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696952.